Glial Progenitor Cell Conversion Using Specific Promoters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating neuronal cells from non-neuronal cells, such as glial progenitor cells, are inefficient and often result in mixed cell populations, leading to variable outcomes in clinical trials for neurodegenerative disorders.
Innovation Solution
A method involving the use of recombinant genetic constructs that include promoters specific to glial progenitor cells, linked with nucleic acid sequences encoding neuronal reprogramming factors, to specifically convert glial progenitor cells into mature neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fetal tissue grafts are used for Parkinson's disease treatment, then functional improvement is achieved, but refractory dyskinesias occur and cell type specificity is lost
Solution Approach 1:
The patent extracts and isolates specific cell types (nigrostriatal dopaminergic neurons and striatal medium spiny neurons) from the heterogeneous fetal tissue, delivering only the needed neuronal populations to the target brain regions. This extraction approach eliminates unnecessary cell types that cause dyskinesias while preserving the functional benefits of neuronal replacement.
Solution Approach 2:
The patent applies local quality by providing cell type-specific neuronal replacement tailored to the particular neurodegenerative condition. For Parkinson's disease, only nigrostriatal dopaminergic neurons are delivered to the striatum, while for Huntington's disease, only striatal medium spiny neurons are provided. This localized, condition-specific approach optimizes functional recovery while minimizing harmful effects.
2Reliability
If fetal striatal grafts are used for Huntington's disease treatment, then neuronal replacement is achieved, but disease-like neuronal degeneration occurs
Solution Approach 1:
The patent extracts and delivers only the specific neuronal population (striatal medium spiny neurons) needed for Huntington's disease treatment, removing other cell types that may contribute to disease-like degeneration. This purified cell type approach maintains neuronal replacement benefits while reducing harmful degenerative effects.
3Productivity
If direct conversion of fibroblasts to neurons is performed, then neuronal generation is achieved, but efficiency is low and mixed cell populations result
Solution Approach 1:
The patent employs preliminary action by first generating induced pluripotent stem cells (iPSCs) from fibroblasts before differentiating them into specific neuronal types. This two-stage process (reprogramming to pluripotency, then directed differentiation) significantly improves conversion efficiency and enables precise control over the final neuronal cell type, eliminating mixed populations.
Solution Approach 2:
The patent segments the complex reprogramming process into distinct stages: (1) conversion of fibroblasts to iPSCs, and (2) differentiation of iPSCs into specific neuronal types. This segmentation allows optimization of each stage independently, improving overall efficiency and precision while avoiding the inefficiency and imprecision of direct fibroblast-to-neuron conversion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient and specific generation of neuronal populations, including medium spiny neurons and cortical interneurons, which can potentially be used to treat neurodegenerative disorders by providing functional neuronal replacement.
Implementation Method 1
a promoter and/or enhancer for a gene which is selectively or specifically expressed by human glial progenitor cells
Data Source
AI summary
The present disclosure is directed to a method of generating a population of neurons. This method involves providing a population of human glial progenitor cells: providing a recombinant genetic construct comprising (i) a promoter and/or enhancer for a gene which is selectively or specifically expressed by human glial progenitor cells, and (ii) a nucleic acid sequence encoding one or more neuronal reprogramming factors for producing neurons from glial progenitor cells, where the nucleic acid sequence is operably linked to the 3′ end of said promoter and/or enhancer to achieve expression of the one or more neuronal reprogramming factors; transfecting cells of the glial progenitor cell population with the recombinant genetic construct; and culturing the population after said transfecting under conditions suitable for neuron production from the transfected glial progenitor cells of the population. Also disclosed are methods of inducing the production of neurons, as well as recombinant genetic constructs.